JAMA Oncology:PET/CT评估的雄激素受体表达和糖酵解活动作为转移性去势抵抗前列腺癌预后分子标志

2017-11-26 MedSci MedSci原创

雄激素受体信号抑制剂可以延长 转移性去势抵抗前列腺癌患者的生存时间,但是最终肿瘤仍会耐药并继续进展。使用18F-FDG或18F-FDHT PET/CT评估雄激素受体表达可以判断影像学亚型的异质性,这一方法有助于鉴别可以从雄激素受体信号抑制剂获得临床获益的患者。JAMA Oncology近期发表了一篇文章,研究PET/CT评估雄激素受体表达及糖酵解活动是否可以反映肿瘤异质性

雄激素受体信号抑制剂可以延长 转移性去势抵抗前列腺癌患者的生存时间,但是最终肿瘤仍会耐药并继续进展。使用18F-FDG或18F-FDHT PET/CT评估雄激素受体表达可以判断影像学亚型的异质性,这一方法有助于鉴别可以从雄激素受体信号抑制剂获得临床获益的患者。JAMA Oncology近期发表了一篇文章,研究PET/CT评估雄激素受体表达及糖酵解活动是否可以反映肿瘤异质性。

作者纳入了2007年4月6日到2012年10月4日之间接受18F-FDG或18F-FDHT PET/CT检查的转移性去势抵抗前列腺癌患者。患者之前未接受过enzalutamide或abiraterone等雄激素受体信号抑制剂的治疗。在影像学阳性区域进行影像引导下活检判断是否有前列腺癌存在。所有的代谢活性区域分为18F-FDHT阳性(AR1)或18F-FDHT阴性(AR0)以及18F-FDG阳性(Glyc1)或18F-FDG阴性(Glyc0)。分析区域影像学亚型以及患者特异性影像学亚型与总生存之间的关系。研究最终纳入133例患者,平均年龄68岁。2405例PET/CT阳性影像学亚型包括1713例AR1Glyc1,386例AR1Glyc0,306例AR0Glyc1。多因素分析表明每一种亚型都对预后有独立负性影响,影响最强的是AR0Glyc1,AR1Glyc1次之,最后是AR1Glyc0。根据区域类型分类时,出现4个患者特异性亚组:1.表达一致组,均为AR1Glyc1(34例患者)2.AR为主组,包括AR1Glyc1以及不同数量的AR1Glyc0(33例患者) 3.Glyc为主组,包括AR1Glyc1以及不同数量的AR0Glyc1(40例患者)4.混合组,包括AR1Glyc1以及不同数量的AR1Glyc0和AR0Glyc1(26例患者)。

文章最后认为,PET/CT影像学亚型异质性在病变及个体患者水平均有临床意义。对于转移性去势抵抗前列腺癌病变,大部分表达ARs,雄激素受体信号抑制剂可以有临床获益。49%的患者(组3和组4)有至少1处AR0GLyc1病变(对生存负性影响最大的亚型),可能是由于雄激素受体抑制剂耐药。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1674430, encodeId=df7916e4430d2, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Wed Oct 31 02:20:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726907, encodeId=e2fd1e2690736, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 01 06:20:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865213, encodeId=7e921865213b6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Jul 06 22:20:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946671, encodeId=75f319466e157, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37232, encryptionId=e61f3e232f7, topicName=去势抵抗前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Fri Jul 13 14:20:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275768, encodeId=788512e576844, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309672, encodeId=979e13096e2fe, content=<a href='/topic/show?id=412114080d1' target=_blank style='color:#2F92EE;'>#PET/CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14080, encryptionId=412114080d1, topicName=PET/CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=295c372, createdName=chaojitidian, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331079, encodeId=a52913310e934, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350524, encodeId=deda135052498, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386316, encodeId=91f4138631626, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264700, encodeId=bd2e264e0074, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Nov 27 09:33:56 CST 2017, time=2017-11-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1674430, encodeId=df7916e4430d2, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Wed Oct 31 02:20:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726907, encodeId=e2fd1e2690736, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 01 06:20:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865213, encodeId=7e921865213b6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Jul 06 22:20:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946671, encodeId=75f319466e157, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37232, encryptionId=e61f3e232f7, topicName=去势抵抗前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Fri Jul 13 14:20:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275768, encodeId=788512e576844, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309672, encodeId=979e13096e2fe, content=<a href='/topic/show?id=412114080d1' target=_blank style='color:#2F92EE;'>#PET/CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14080, encryptionId=412114080d1, topicName=PET/CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=295c372, createdName=chaojitidian, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331079, encodeId=a52913310e934, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350524, encodeId=deda135052498, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386316, encodeId=91f4138631626, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264700, encodeId=bd2e264e0074, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Nov 27 09:33:56 CST 2017, time=2017-11-27, status=1, ipAttribution=)]
    2018-05-01 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1674430, encodeId=df7916e4430d2, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Wed Oct 31 02:20:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726907, encodeId=e2fd1e2690736, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 01 06:20:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865213, encodeId=7e921865213b6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Jul 06 22:20:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946671, encodeId=75f319466e157, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37232, encryptionId=e61f3e232f7, topicName=去势抵抗前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Fri Jul 13 14:20:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275768, encodeId=788512e576844, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309672, encodeId=979e13096e2fe, content=<a href='/topic/show?id=412114080d1' target=_blank style='color:#2F92EE;'>#PET/CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14080, encryptionId=412114080d1, topicName=PET/CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=295c372, createdName=chaojitidian, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331079, encodeId=a52913310e934, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350524, encodeId=deda135052498, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386316, encodeId=91f4138631626, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264700, encodeId=bd2e264e0074, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Nov 27 09:33:56 CST 2017, time=2017-11-27, status=1, ipAttribution=)]
    2018-07-06 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=1674430, encodeId=df7916e4430d2, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Wed Oct 31 02:20:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726907, encodeId=e2fd1e2690736, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 01 06:20:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865213, encodeId=7e921865213b6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Jul 06 22:20:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946671, encodeId=75f319466e157, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37232, encryptionId=e61f3e232f7, topicName=去势抵抗前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Fri Jul 13 14:20:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275768, encodeId=788512e576844, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309672, encodeId=979e13096e2fe, content=<a href='/topic/show?id=412114080d1' target=_blank style='color:#2F92EE;'>#PET/CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14080, encryptionId=412114080d1, topicName=PET/CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=295c372, createdName=chaojitidian, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331079, encodeId=a52913310e934, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350524, encodeId=deda135052498, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386316, encodeId=91f4138631626, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264700, encodeId=bd2e264e0074, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Nov 27 09:33:56 CST 2017, time=2017-11-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1674430, encodeId=df7916e4430d2, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Wed Oct 31 02:20:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726907, encodeId=e2fd1e2690736, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 01 06:20:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865213, encodeId=7e921865213b6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Jul 06 22:20:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946671, encodeId=75f319466e157, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37232, encryptionId=e61f3e232f7, topicName=去势抵抗前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Fri Jul 13 14:20:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275768, encodeId=788512e576844, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309672, encodeId=979e13096e2fe, content=<a href='/topic/show?id=412114080d1' target=_blank style='color:#2F92EE;'>#PET/CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14080, encryptionId=412114080d1, topicName=PET/CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=295c372, createdName=chaojitidian, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331079, encodeId=a52913310e934, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350524, encodeId=deda135052498, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386316, encodeId=91f4138631626, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264700, encodeId=bd2e264e0074, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Nov 27 09:33:56 CST 2017, time=2017-11-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1674430, encodeId=df7916e4430d2, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Wed Oct 31 02:20:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726907, encodeId=e2fd1e2690736, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 01 06:20:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865213, encodeId=7e921865213b6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Jul 06 22:20:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946671, encodeId=75f319466e157, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37232, encryptionId=e61f3e232f7, topicName=去势抵抗前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Fri Jul 13 14:20:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275768, encodeId=788512e576844, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309672, encodeId=979e13096e2fe, content=<a href='/topic/show?id=412114080d1' target=_blank style='color:#2F92EE;'>#PET/CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14080, encryptionId=412114080d1, topicName=PET/CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=295c372, createdName=chaojitidian, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331079, encodeId=a52913310e934, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350524, encodeId=deda135052498, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386316, encodeId=91f4138631626, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264700, encodeId=bd2e264e0074, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Nov 27 09:33:56 CST 2017, time=2017-11-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1674430, encodeId=df7916e4430d2, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Wed Oct 31 02:20:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726907, encodeId=e2fd1e2690736, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 01 06:20:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865213, encodeId=7e921865213b6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Jul 06 22:20:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946671, encodeId=75f319466e157, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37232, encryptionId=e61f3e232f7, topicName=去势抵抗前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Fri Jul 13 14:20:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275768, encodeId=788512e576844, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309672, encodeId=979e13096e2fe, content=<a href='/topic/show?id=412114080d1' target=_blank style='color:#2F92EE;'>#PET/CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14080, encryptionId=412114080d1, topicName=PET/CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=295c372, createdName=chaojitidian, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331079, encodeId=a52913310e934, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350524, encodeId=deda135052498, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386316, encodeId=91f4138631626, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264700, encodeId=bd2e264e0074, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Nov 27 09:33:56 CST 2017, time=2017-11-27, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1674430, encodeId=df7916e4430d2, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Wed Oct 31 02:20:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726907, encodeId=e2fd1e2690736, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 01 06:20:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865213, encodeId=7e921865213b6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Jul 06 22:20:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946671, encodeId=75f319466e157, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37232, encryptionId=e61f3e232f7, topicName=去势抵抗前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Fri Jul 13 14:20:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275768, encodeId=788512e576844, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309672, encodeId=979e13096e2fe, content=<a href='/topic/show?id=412114080d1' target=_blank style='color:#2F92EE;'>#PET/CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14080, encryptionId=412114080d1, topicName=PET/CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=295c372, createdName=chaojitidian, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331079, encodeId=a52913310e934, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350524, encodeId=deda135052498, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386316, encodeId=91f4138631626, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264700, encodeId=bd2e264e0074, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Nov 27 09:33:56 CST 2017, time=2017-11-27, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1674430, encodeId=df7916e4430d2, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Wed Oct 31 02:20:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726907, encodeId=e2fd1e2690736, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 01 06:20:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865213, encodeId=7e921865213b6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Jul 06 22:20:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946671, encodeId=75f319466e157, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37232, encryptionId=e61f3e232f7, topicName=去势抵抗前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Fri Jul 13 14:20:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275768, encodeId=788512e576844, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309672, encodeId=979e13096e2fe, content=<a href='/topic/show?id=412114080d1' target=_blank style='color:#2F92EE;'>#PET/CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14080, encryptionId=412114080d1, topicName=PET/CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=295c372, createdName=chaojitidian, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331079, encodeId=a52913310e934, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350524, encodeId=deda135052498, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386316, encodeId=91f4138631626, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264700, encodeId=bd2e264e0074, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Nov 27 09:33:56 CST 2017, time=2017-11-27, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1674430, encodeId=df7916e4430d2, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Wed Oct 31 02:20:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726907, encodeId=e2fd1e2690736, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 01 06:20:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865213, encodeId=7e921865213b6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Jul 06 22:20:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946671, encodeId=75f319466e157, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37232, encryptionId=e61f3e232f7, topicName=去势抵抗前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Fri Jul 13 14:20:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275768, encodeId=788512e576844, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309672, encodeId=979e13096e2fe, content=<a href='/topic/show?id=412114080d1' target=_blank style='color:#2F92EE;'>#PET/CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14080, encryptionId=412114080d1, topicName=PET/CT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=295c372, createdName=chaojitidian, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331079, encodeId=a52913310e934, content=<a href='/topic/show?id=15e2140e438' target=_blank style='color:#2F92EE;'>#PET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14074, encryptionId=15e2140e438, topicName=PET)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350524, encodeId=deda135052498, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386316, encodeId=91f4138631626, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Nov 28 00:20:00 CST 2017, time=2017-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=264700, encodeId=bd2e264e0074, content=学习了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Mon Nov 27 09:33:56 CST 2017, time=2017-11-27, status=1, ipAttribution=)]
    2017-11-27 明天会更好!

    学习了.谢谢分享!

    0

相关资讯

NEJM:转移性前列腺癌DNA-修复基因突变率远高于局部前列腺癌

DNA-修复基因如BRCA2的基因突变与致命性前列腺癌的发病风险增加相关。虽然局部前列腺癌患者的DNA修复基因突变的发生率是不足以保证常规检测,但是转移性前列腺癌患者的这种基因突变的频率尚未确定。 研究共纳入692名转移性前列腺癌患者,分离生殖细胞的DNA,并使用多重测序分析来评估在20个DNA修复基因与常染色体显性遗传性癌症易感综合征相关的突变。 结果,82名男性(11.8%)中共发

BMJ研究新闻:转移性前列腺癌治疗时手术去势治疗较药物治疗的副作用少

据发表于JAMA Oncology的一项新的研究发现,对于转移性前列腺癌患者,与睾丸切除术相比,药物去势治疗的副作用发生率较高。

NEJM:多西他赛加ADT治疗显著延长转移性前列腺癌患者的总生存期

雄激素剥夺疗法(ADT)自19世纪40年代以来已经作为转移性前列腺癌的主要疗法。研究人员评估使用ADT加多西他赛联合治疗是否会比单独的ADT治疗有更长的整体存活期。    研究人员分配转移性激素敏感性前列腺癌男性患者接受ADT加多西他赛(剂量为每平方米体表面积75毫克,每3周一个周期,共六个周期)治疗或ADT单独治疗。主要目的是测试接受多西他赛加ADT疗法比接受单独A

J Urol:促性腺激素释放激素基因编码多态性与ADT期间血清睾酮水平之间的联系及与转移性前列腺癌预后的关系。

据报道,在使用雄激素剥夺疗法(ADT)治疗转移性前列腺癌时对血清睾酮水平的抑制会影响ADT的疗效。然而,影响ADT期间激素变化的因素仍不清楚。因此,在这项研究中,研究者研究了在主要以ADT疗法为主的转移性前列腺癌患者中,促性腺激素释放激素(GnRH)的基因编码中错义多态性的意义。